Fibrosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Fibrosis – Pipeline Review, H1 2017’, provides an overview of the Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Fibrosis

– The report reviews pipeline therapeutics for Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acceleron Pharma Inc

Aelis Farma SAS

Allakos Inc

Anima Biotech Ltd

Bristol-Myers Squibb Company

Calypso Biotech SA

Complexa Inc

Encycle Therapeutics Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Genfit SA

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

iBio Inc

Immunomet Therapeutics Inc

Inception Sciences Inc

Insmed Inc

Inventiva

Ironwood Pharmaceuticals Inc

Isarna Therapeutics GmbH

Lycera Corp

Neumedicines Inc

Novartis AG

Palatin Technologies Inc

Ribomic Inc

Scholar Rock Inc

SciFluor Life Sciences LLC

SK Chemicals Co Ltd

UCB SA

VivaCell Biotechnology Espana SL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Fibrosis Overview 8

Fibrosis Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Fibrosis Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Fibrosis Companies Involved in Therapeutics Development 29

Acceleron Pharma Inc 29

Aelis Farma SAS 29

Allakos Inc 30

Anima Biotech Ltd 30

Bristol-Myers Squibb Company 31

Calypso Biotech SA 31

Complexa Inc 32

Encycle Therapeutics Inc 32

F. Hoffmann-La Roche Ltd 33

Five Prime Therapeutics Inc 33

Genfit SA 34

GlycoMimetics Inc 34

Hanmi Pharmaceuticals Co Ltd 35

iBio Inc 35

Immunomet Therapeutics Inc 36

Inception Sciences Inc 36

Insmed Inc 37

Inventiva 37

Ironwood Pharmaceuticals Inc 38

Isarna Therapeutics GmbH 38

Lycera Corp 39

Neumedicines Inc 39

Novartis AG 40

Palatin Technologies Inc 40

Ribomic Inc 41

Scholar Rock Inc 41

SciFluor Life Sciences LLC 42

SK Chemicals Co Ltd 42

UCB SA 43

VivaCell Biotechnology Espana SL 43

Fibrosis Drug Profiles 44

ACE-2798 Drug Profile 44

AEF-0118 Drug Profile 45

AK-002 Drug Profile 46

Antibody to Inhibit Transglutaminase 2 for Fibrosis Drug Profile 48

CALY-001 Drug Profile 49

CWHM-12 Drug Profile 50

elafibranor Drug Profile 51

G-XXX Drug Profile 60

IB-DMD Drug Profile 61

IBIOCFB-03 Drug Profile 62

IM-156 Drug Profile 64

INS-1007 Drug Profile 65

ISTH-1106 Drug Profile 66

IW-1701 Drug Profile 67

IW-1973 Drug Profile 68

LYC-53976 Drug Profile 70

Monoclonal Antibodies for Fibrosis Drug Profile 71

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis Drug Profile 72

Monoclonal Antibody 2 for Fibrosis Drug Profile 73

Monoclonal Antibody for Fibrotic Scar Drug Profile 74

Monoclonal Antibody to Activate BMP7 for Fibrosis Drug Profile 75

NCE-401 Drug Profile 76

Neumomir Drug Profile 77

NMIL-121 Drug Profile 78

OCX-063 Drug Profile 82

PAT-048 Drug Profile 83

PL-5028 Drug Profile 84

PRI-724 Drug Profile 85

Proteins for Central Nervous System Disorders and Fibrosis Drug Profile 87

RBM-003 Drug Profile 88

RBM-007 Drug Profile 89

Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis Drug Profile 90

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders Drug Profile 91

RG-6125 Drug Profile 92

Small Molecule for Fibrosis Drug Profile 94

Small Molecule for Fibrosis Drug Profile 95

Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease Drug Profile 96

Small Molecule to Inhibit LOXL2 for Fibrosis Drug Profile 97

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis Drug Profile 98

Small Molecules for Fibrosis Drug Profile 99

Small Molecules for Fibrosis Drug Profile 100

Small Molecules for Fibrosis Drug Profile 101

Small Molecules for Fibrosis Drug Profile 102

Small Molecules for Fibrosis Drug Profile 103

Small Molecules for Fibrosis Drug Profile 104

Small Molecules for Fibrosis and Inflammatory Diseases Drug Profile 105

Small Molecules for Fibrosis and Oncology Drug Profile 106

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis Drug Profile 107

Small Molecules to Antagonize Integrin Alpha V for Fibrosis Drug Profile 108

Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease Drug Profile 109

Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology Drug Profile 110

Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology Drug Profile 111

SRI-31277 Drug Profile 112

ST-2001 Drug Profile 113

Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology Drug Profile 114

VCE-0048 Drug Profile 115

X-165 Drug Profile 116

XOMA-089 Drug Profile 117

Fibrosis Dormant Projects 118

Fibrosis Product Development Milestones 120

Featured News & Press Releases 120

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

List of Tables

Number of Products under Development for Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Fibrosis Pipeline by Acceleron Pharma Inc, H1 2017

Fibrosis Pipeline by Aelis Farma SAS, H1 2017

Fibrosis Pipeline by Allakos Inc, H1 2017

Fibrosis Pipeline by Anima Biotech Ltd, H1 2017

Fibrosis Pipeline by Bristol-Myers Squibb Company, H1 2017

Fibrosis Pipeline by Calypso Biotech SA, H1 2017

Fibrosis Pipeline by Complexa Inc, H1 2017

Fibrosis Pipeline by Encycle Therapeutics Inc, H1 2017

Fibrosis Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Fibrosis Pipeline by Five Prime Therapeutics Inc, H1 2017

Fibrosis Pipeline by Genfit SA, H1 2017

Fibrosis Pipeline by GlycoMimetics Inc, H1 2017

Fibrosis Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Fibrosis Pipeline by iBio Inc, H1 2017

Fibrosis Pipeline by Immunomet Therapeutics Inc, H1 2017

Fibrosis Pipeline by Inception Sciences Inc, H1 2017

Fibrosis Pipeline by Insmed Inc, H1 2017

Fibrosis Pipeline by Inventiva, H1 2017

Fibrosis Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Fibrosis Pipeline by Isarna Therapeutics GmbH, H1 2017

Fibrosis Pipeline by Lycera Corp, H1 2017

Fibrosis Pipeline by Neumedicines Inc, H1 2017

Fibrosis Pipeline by Novartis AG, H1 2017

Fibrosis Pipeline by Palatin Technologies Inc, H1 2017

Fibrosis Pipeline by Ribomic Inc, H1 2017

Fibrosis Pipeline by Scholar Rock Inc, H1 2017

Fibrosis Pipeline by SciFluor Life Sciences LLC, H1 2017

Fibrosis Pipeline by SK Chemicals Co Ltd, H1 2017

Fibrosis Pipeline by UCB SA, H1 2017

Fibrosis Pipeline by VivaCell Biotechnology Espana SL, H1 2017

Fibrosis Dormant Projects, H1 2017

Fibrosis Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports